

The anti-inflammatory peptide Catestatin blocks chemotaxis

1 **Elke M. Muntjewerff¹, Kristel Parv², Sushil K. Mahata^{3,4}, Mia Phillipson^{2,5}, Gustaf**
2 **Christoffersson^{2,5*}, Geert van den Bogaart^{1,6*}**

3 ¹ Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences,
4 Radboud University Medical Center, Nijmegen, the Netherlands

5 ² Department of Medical Cell biology, Uppsala University, Uppsala, Sweden

6 ³ VA San Diego Healthcare System and

7 ⁴ Department of Medicine, University of California San Diego, La Jolla, California, USA

8 ⁵ Science for Life Laboratory, Uppsala University, Uppsala, Sweden

9 ⁶ Department of Molecular Immunology and Microbiology, Groningen Biomolecular Sciences
10 and Biotechnology Institute, University of Groningen, Groningen, the Netherlands.

11 *** Correspondence:**

12 Geert van den Bogaart: g.van.den.bogaart@rug.nl

13 Gustaf Christoffersson: gustaf.christoffersson@scilifelab.uu.se

14 **Keywords: Catestatin¹, Macrophages², Monocytes³, Pro-angiogenesis⁴, Granulocytes⁵,**
15 **Chemotaxis⁶, Migration⁷**

16 Word count: 1.468

17 Figures: 2

18 **Abstract**

19 Increased levels of the anti-inflammatory peptide catestatin (CST), a cleavage product of the
20 pro-hormone chromogranin A, correlates with less severe outcomes in hypertension, colitis and
21 diabetes. However, it is unknown how CST reduces the infiltration of monocytes and
22 macrophages in inflamed tissues. Here, we report that CST blocks leukocyte migration towards
23 inflammatory chemokines. By *in vitro* and *in vivo* migration assays, we show that although CST
24 itself is weakly chemotactic, it blocks migration of monocytes and granulocytes to
25 inflammatory attracting factor CC-chemokine ligand 2 (CCL2) and macrophage inflammatory
26 protein 2 (MIP-2). Moreover, it directs CX₃CR1⁺ macrophages away from pancreatic islets.
27 These findings support the emerging notion that CST is a key anti-inflammatory modulator.
28

29 **1. Introduction**

30
31 As an immunological response to inflammation, monocytes, granulocytes and leukocytes
32 are attracted to inflamed tissues by chemokines such as CC-chemokine ligand 2 (CCL2,
33 a.k.a. MCP-1) and macrophage inflammatory protein 2 (MIP-2, a.k.a. CXCL2) (1).
34 However, to avoid an excessive response, leukocyte infiltration should be halted for
35 resolution of inflammation, but the mechanisms that govern this are unknown (2). Here, we
36 addressed the potential chemotactic effect of chromogranin A (CgA)-derived peptide
37 Catestatin (CST: hCgA₃₅₂₋₃₇₂) (3). While CST circulates at low nM range, the local
38 concentrations were detected in the μM range in mouse tissues (3–6).

39 Being an anti-inflammatory peptide, CST reduces inflammation in cardiac and chronic
40 inflammatory diseases (3,7–9). Despite the chemotactic effects of CST (7,10,11),
41 administration of exogenous CST reduces monocyte and macrophage infiltration in the
42 liver, heart and gut in mouse models of type II diabetes, hypertension, atherosclerosis and
43 colitis (4,7,8,12,13). In a colitis model, CST also reduced granulocyte infiltration in the
44 colon (8). In line with this, the adrenal gland, heart, and gut of CST knockout mice display
45 increased macrophage infiltration (4,7,12). In this study, we show that while CST itself is
46 weakly chemotactic, it blocks the extravasation and migration of phagocytes both *in vitro*
47 and *in vivo*. Thus, the anti-inflammatory effects of CST are partly the result of redirecting
48 monocytes and granulocytes away from the inflammation sites.
49

50 **2. Methods; experimental procedures**

51 *2.1 Animals and human bloods samples*

52 Male and female C57BL/6J (Taconic, Denmark) and *Cx3cr1^{GFP}* (14) mice weighing 20-26
53 g were used. All animal experiments were approved by the Regional Animal Ethics
54 committee in Uppsala, Sweden. The research with human blood samples at the Department
55 of Tumor Immunology complies with all institutional and national ethics regulations and
56 has been approved by the ethics committee of Sanquin blood bank. All blood donors were
57 informed of the research and have granted their consent.
58

59 *2.2 Gradientech assay*

60 A CellDirector 2D device (Gradientech) was coated with bovine serum overnight. Human
61 peripheral blood monocytes were isolated from buffy coats of healthy donors as described
62 (15), followed by human microbead CD14⁺ isolation of monocytes according to
63 manufactures' instructions (130-050-201, Milteny Biotec). Monocytes were activated with
64 LPS for 1 h, washed with PBS, and seeded in the device in 200 μ l RPMI-1640 medium.
65 After one hour at 37°C, the two supplied syringes with 1 ml of RPMI-1640 medium, with
66 one containing 5 μ M CST were attached to the CellDirector and a flow rate of 5 μ l/min was
67 applied. Monocyte movement was visualized with an Axiovert 200 M microscope with a
68 5x objective (Zeiss, Jena, Germany). Movies were recorded at 2 frames/min for 3 hours.
69 Cell movement was analysed using the Tracking Tool PRO software (Gradientech). 0.5 nM
70 CCL2 (300-04, PeproTech) was used as a positive control.
71

72 *2.3 Cremaster muscle imaging*

73 Monocyte and granulocyte (Ly6G-mAb) migration was imaged in the cremaster muscle of
74 mice superfused with pre-warmed (37°C) bicarbonate-buffered saline solution (pH 7.4) (16)
75 containing CST (5 μ M) and/or MIP-2/CXCL2 (0.5 nM) (250-15, PeproTech) was used as
76 a positive control. A bright-field intravital microscope (Leica DM5000B) with a 25 \times /0.6W
77 (Leica) objective and connected to an Orca R2 camera (Hamamatsu; Volocity acquisition
78 software) was used to record movies of five minutes at 0, 30, 60, 90 min after cytokine
79 addition. Venules with diameter range of 20-30 μ m were imaged. Movies were analysed
80 using ImageJ and corrected using the Hyperstackreg ImageJ macro. For rolling flux, all
81 cells rolling in the vessel were counted. For rolling speed, velocity over a 100 μ m section
82 of the vessel was analysed. In the same 100 μ m section, cells were considered adherent if
83 they remained stationary for at least 3 min.
84

85 *2.4 Aortic ring assay with pancreatic islet culture*

86 Aortic ring isolation was carried out as previously described (17). Briefly, 13-16-week-old
87 *Cx3cr1^{GFP}* mice were euthanized, followed by dissection of the thoracic aorta. Under a
88 stereo-microscope, extraneous fat, tissue, and branching vessels were carefully removed,

89 and perfused with serum-free OptiMEM medium (Thermo Fisher) with penicillin-
90 streptomycin solution. The aorta was sectioned into 1 mm thick rings. After overnight
91 starvation in serum-free Opti-MEM medium, rings were embedded in 1 mg/ml rat tail
92 collagen I (#ALX-522-435-0100, Enzo Life sciences) adjacent to pancreatic islets (2-5 islets
93 per ring), which were isolated from C57BL/6 mice as described before (18), in 8 well Nunc
94 Lab-Tek II microscope chambers (Thermo Fisher). After 1 h, embedded rings were cultured
95 with 300 μ l of OptiMEM with 2.5% FBS, 11.1 mM glucose, penicillin-streptomycin, M-
96 CSF (40 ng/ml) to stimulate CX₃CR1^{GFP+} macrophage survival and 5 μ M CST for six days.
97 On day six, rings were imaged using a Zeiss LSM700 (Carl Zeiss) confocal microscope.
98 The numbers of CX₃CR1^{GFP+} cells were quantified using the image analysis software Imaris
99 (Bitplane). The location of the CX₃CR1^{GFP+} cells was determined using the Surface Center
100 of Mass Position to Spots object plugin after manually defining the aorta. For analyzing
101 angiogenesis, staining with anti-CD31 antibody conjugated to Alexa Fluor 647 (#102515,
102 Biologend) was carried out prior to imaging. Aortic rings that did not show any sprouting
103 were excluded from further analysis. Vessels were analyzed using Fiji image analysis
104 software (19). Sprouts that originated directly from the ring endothelium were considered
105 main sprouts, and branches as divarications from main sprouts.
106

107 2.5 Statistical data analysis

108 Data are expressed as mean \pm SEM. One-way ANOVA with Bonferroni post-hoc tests or
109 non-parametric Mann-Whitney test were applied for multiple comparisons. Outliers were
110 identified using ROUT test (Q=1%). A value of $p < 0.05$ was considered statistically
111 significant.
112

113 3. Results & Discussion

114 Although human blood monocytes migrated towards a high (but physiological)
115 concentration of CST (5 μ M), this was less efficient compared to the canonical
116 inflammatory chemokine CCL2 (0.5 nM) (Fig. 1A-C), reinforcing a weak chemoattractive
117 effect of CST (7,10,11). To confirm this *in vivo*, we performed imaging of the cremaster
118 muscle (Fig. 1D) (16). Upon perfusion of the muscle with CST (5 μ M), phagocytes
119 (monocytes and granulocytes) decreased their speed and attached to the vessel wall with
120 similar efficiency as of the inflammatory chemotactic agent MIP-2 (0.5 nM) (Fig. 1D-F,
121 Fig. S1). Thus, both our *in vivo* and *in vitro* migration assays show that CST is weakly
122 chemotactic, raising the question how CST can reduce monocyte and granulocyte
123 infiltration in inflamed tissues such as the liver (diet induced obese mice), intestine (colitis
124 model), heart (hypertension model) and atheromatous plaques (atherosclerosis model)
125 (4,7,8,12,13).
126

127 To address how CST affects macrophage chemotaxis to inflamed tissues, we used the aortic
128 ring vessel model (17) (Fig. 2A), which is based on the co-embedding of part of the aorta
129 of *Cx3cr1*^{+/*gfp*} transgenic mice adjacent to isolated pancreatic islets (20). These islets secrete
130 chemokines, such as vascular endothelial growth factor (VEGF)-A, resulting in the
131 directional macrophage migration from the aortic ring as well as vessel growth towards the
132 pancreatic islets. Migration of CX₃CR1⁺ macrophages from the aortic ring was visualized
133 by fluorescence microscopy (19) (Fig. 2B, S2). As expected, the CX₃CR1-macrophages
134 moved towards the pancreatic islets in absence of CST (Fig 2B). However, perfusing the
135 aortic ring with CST (5 μ M) resulted in a lower number of CX₃CR1^{+GFP} macrophages
136 migrating towards the pancreatic islets (Fig 2B), indicating that CST blocked directional
137 migration. Interestingly, we also observed that CST is pro-angiogenic, as it increased both

138 the amount and length of the sprouts and branches emanating from the aortic rings (Fig. 2C-
139 D, S3).

140

141 The loss of directional cell migration to the pancreatic islets might be caused by blockage
142 of chemokine-induced cell migration by CST. To investigate this possibility, we performed
143 intravital imaging of the cremaster muscle, but this time for CST in combination with MIP-
144 2. This resulted in the inverse effect compared to CST or MIP-2 alone: release of attached
145 cells from the vessel wall and reduced migration of cells into the tissue (Fig. 2E, S4),
146 indicating that despite being weakly chemotactic, CST blocks MIP-2 elicited phagocyte
147 recruitment. To further confirm this, we performed an *in vitro* migration assay, where
148 human monocytes were stimulated with a gradient of CCL2 in presence of CST (Fig. 2F).
149 Similar to our findings with the intravital imaging, CST blocked monocyte migration
150 towards the CCL2.

151

152 Although CST counteracts the chemoattraction by inflammatory cytokines (Fig. 2G), the
153 question remains open which receptor(s) CST utilize to exert these effects on cell migration.
154 We speculate that this might be a G-protein coupled receptor (GPCR), since GPCRs are
155 actively involved in leukocyte migration (21) coupled with expression of GPCRs in all cell
156 types responsive to catenestatin (e.g. monocytes (10), neutrophils (22,23), macrophages
157 (4,7,8,12,13), endothelial (13,24) and mast cells (11)), we speculate that CST might act
158 through this receptor type. We have not only shown how CST reduces the infiltration of
159 monocytes and macrophages in inflamed tissues (4,7,8,12,13), but offer a possible
160 mechanistic explanation for the correlation of CST levels with improved disease outcome
161 in patients suffering from chronic diseases (4–6), reinforcing CST as a therapeutic target
162 for treatment of diseases associated with chronic inflammation.

163

164 4. Author contributions

165 E.M.M., G.C., S.K.M. and G.v.d.B. designed the study. E.M.M, K.P., G.C. designed and
166 performed the experiments. E.M.M. and G.v.d.B wrote the manuscript and all authors
167 participated in discussing and editing of the manuscript.

168

169 5. Disclosure of conflict of interest

170 The authors declare that the research was conducted in the absence of any commercial or
171 financial relationships that could be construed as a potential conflict of interest.

172

173 6. Funding

174 G.v.d.B. is funded by a Young Investigator Grant from the Human Frontier Science
175 Program (HFSP; RGY0080/2018), and a Vidi grant from the Netherlands Organization for
176 Scientific Research (NWO-ALW VIDI 864.14.001). G.v.d.B has received funding from the
177 European Research Council (ERC) under the European Union's Horizon 2020 research and
178 innovation programme (grant agreement No. 862137. S.K.M. is supported by a grant from
179 the US Department of Veterans Affairs (I01BX000323). G.C. is supported by grants from
180 the Swedish Research Council and the Swedish Society for Medical Research. E.M.M is
181 supported by a short-term EMBO fellowship (EMBO7887).

182

183

184

185 7. References

186

1. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Review Monocyte Chemoattractant

- 187 Protein-1 (MCP-1): An Overview. doi:10.1089/jir.2008.0027
- 188 2. Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM. Resolution of
189 inflammation: What controls its onset? *Front Immunol* (2016) **7**:
190 doi:10.3389/fimmu.2016.00160
- 191 3. Muntjewerff EM, Dunkel G, Nicolassen MJT, Mahata SK, Van Den Bogaart G.
192 Catestatin as a Target for Treatment of Inflammatory Diseases. *Front Immunol* (2018)
193 **9**:2199. doi:10.3389/fimmu.2018.02199
- 194 4. Muntjewerff EM, Tang K, Lutter L, Gustaf C, Nicolassen MJT, Gao H, Katkar GD, Das
195 S, ter Beest B, Ying W, et al. Chromogranin A regulates gut permeability via the
196 antagonistic actions of its proteolytic peptides. (2020) Available at:
197 <https://www.biorxiv.org/content/10.1101/2020.09.19.304303v1.full.pdf>
- 198 5. Zivkovic PM, Matetic A, Tadin Hadjina I, Rusic D, Vilovic M, Supe-Domic D,
199 Borovac JA, Mudnic I, Tonkic A, Bozic J. Serum Catestatin Levels and Arterial
200 Stiffness Parameters Are Increased in Patients with Inflammatory Bowel Disease. *J*
201 *Clin Med* (2020) **9**:628. doi:10.3390/jcm9030628
- 202 6. Corti A, Marcucci F, Bachetti T. Circulating chromogranin A and its fragments as
203 diagnostic and prognostic disease markers. *Pflügers Arch - Eur J Physiol* (2017)
204 **470**:199–210. doi:10.1007/s00424-017-2030-y
- 205 7. Ying W, Mahata S, Bandyopadhyay GK, Zhou Z, Wollam J, Vu J, Mayoral R, Chi N-
206 W, Webster NJG, Corti A, et al. Catestatin Inhibits Obesity-Induced Macrophage
207 Infiltration and Inflammation in the Liver and Suppresses Hepatic Glucose Production,
208 Leading to Improved Insulin Sensitivity. *Diabetes* (2018) **67**:841–848.
209 doi:10.2337/db17-0788
- 210 8. Rabbi MF, Labis B, Metz-Boutigue MH, Bernstein CN, Ghia J-E. Catestatin decreases
211 macrophage function in two mouse models of experimental colitis. *Biochem*
212 *Pharmacol* (2014) **89**:386–398. doi:10.1016/j.bcp.2014.03.003
- 213 9. Mahapatra NR, O'Connor DT, Vaingankar SM, Hikim APS, Mahata M, Ray S, Staite
214 E, Wu H, Gu Y, Dalton N, et al. Hypertension from targeted ablation of chromogranin
215 A can be rescued by the human ortholog. *J Clin Invest* (2005) **115**:1942–1952.
216 doi:10.1172/jci24354
- 217 10. Egger M, Beer AGE, Theurl M, Schgoer W, Hotter B, Tatarczyk T, Vasiljevic D,
218 Frauscher S, Marksteiner J, Patsch JR, et al. Monocyte migration: A novel effect and
219 signaling pathways of catestatin. *Eur J Pharmacol* (2008) **598**:104–111.
220 doi:10.1016/j.ejphar.2008.09.016
- 221 11. Aung G, Niyonsaba F, Ushio H, Kajiwara N, Saito H, Ikeda S, Ogawa H, Okumura K.
222 Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration,
223 degranulation and production of cytokines and chemokines. *Immunology* (2011)
224 **132**:527–539. doi:10.1111/j.1365-2567.2010.03395.x
- 225 12. Ying W, Tang K, Avolio E, Schilling JM, Pasqua T, Liu MA, Cheng H, Zhang J,
226 Mahata S, Bandyopadhyay G, et al. Catestatin (CST) is a key mediator of the
227 immunoendocrine regulation of cardiovascular function. (2020) Available at:

- 228 <https://doi.org/10.1101/2020.05.12.092254>
- 229 13. Kojima M, Ozawa N, Mori Y, Takahashi Y, Watanabe-Kominato K, Shirai R,
230 Watanabe R, Sato K, Matsuyama T, Ishibashi-Ueda H, et al. Catestatin Prevents
231 Macrophage-Driven Atherosclerosis but Not Arterial Injury–Induced Neointimal
232 Hyperplasia. *Thromb Haemost* (2018) **118**:182–194. doi:10.1160/TH17-05-0349
- 233 14. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, Littman DR.
234 Analysis of Fractalkine Receptor CX3CR1 Function by Targeted Deletion and Green
235 Fluorescent Protein Reporter Gene Insertion. *Mol Cell Biol* (2000) **20**:4106–4114.
236 doi:10.1128/mcb.20.11.4106-4114.2000
- 237 15. Baranov MV, Bianchi F, Schirmacher A, van Aart MAC, Maassen S, Muntjewerff EM,
238 Dingjan I, ter Beest M, Verdoes M, Keyser SGL, et al. The Phosphoinositide Kinase
239 PIKfyve Promotes Cathepsin-S-Mediated Major Histocompatibility Complex Class II
240 Antigen Presentation. *iScience* (2019) **11**: doi:10.1016/j.isci.2018.12.015
- 241 16. Massena S, Christoffersson G, Hjertström E, Zcharia E, Vlodaysky I, Ausmees N,
242 Rolny C, Li J-P, Phillipson M. A chemotactic gradient sequestered on endothelial
243 heparan sulfate induces directional intraluminal crawling of neutrophils. *Blood* (2010)
244 **116**:1924–1931. doi:10.1182/blood-2010-01-266072
- 245 17. Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D’Amico G, Jones DT,
246 Vojnovic B, Hodivala-Dilke K. Use of the mouse aortic ring assay to study
247 angiogenesis. *Nat Protoc* (2012) **7**:89–104. doi:10.1038/nprot.2011.435
- 248 18. Bohman S, Andersson A, King A. No differences in efficacy between noncultured and
249 cultured islets in reducing hyperglycemia in a nonvascularized islet graft model.
250 *Diabetes Technol Ther* (2006) **8**:536–545. doi:10.1089/dia.2006.8.536
- 251 19. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch
252 S, Rueden C, Saalfeld S, Schmid B, et al. Fiji: An open-source platform for biological-
253 image analysis. *Nat Methods* (2012) **9**:676–682. doi:10.1038/nmeth.2019
- 254 20. Nicosia RF, Gelati M, Aplin AC, Fogel E, Smith KD. Macrophages Requires Injury
255 and Inflammatory Cytokines The Angiogenic Response of the Aorta to. *J Immunol Ref*
256 (2008) **181**:5711–5719. doi:10.4049/jimmunol.181.8.5711
- 257 21. Lämmermann T, Kastenmüller W. Concepts of GPCR-controlled navigation in the
258 immune system. *Immunol Rev* (2019) **289**:205–231. doi:10.1111/imr.12752
- 259 22. Zhang D, Shooshtarizadeh P, Laventie BJ, Colin DA, Chich JF, Vidic J, de Barry J,
260 Chasserot-Golaz S, Delalande F, Van Dorsselaer A, et al. Two chromogranin a-derived
261 peptides induce calcium entry in human neutrophils by calmodulin-regulated calcium
262 independent phospholipase A2. *PLoS One* (2009) **4**:e4501.
263 doi:10.1371/journal.pone.0004501
- 264 23. Briolat J, Wu SD, Mahata SK, Gonthier B, Bagnard D, Chasserot-Golaz S, Helle KB,
265 Aunis D, Metz-Boutigue MH. New antimicrobial activity for the catecholamine
266 release-inhibitory peptide from chromogranin A. *Cell Mol Life Sci* (2005) **62**:377–385.
267 doi:10.1007/s00018-004-4461-9

- 268 24. Theurl M, Schgoer W, Albrecht K, Jeschke J, Egger M, Beer AGE, Vasiljevic D, Rong
269 S, Wolf AM, Bahlmann FH, et al. The Neuropeptide Catestatin Acts As a Novel
270 Angiogenic Cytokine via a Basic Fibroblast Growth Factor-Dependent Mechanism.
271 *Circ Res* (2010) **107**:1326–1335. doi:10.1161/circresaha.110.219493

272
273 **8. Figure legends**
274

275 **Fig. 1: CST is weakly chemotactic.** (A) Scheme showing set-up of Gradientech migration
276 assay. Two syringes filled with buffer +/- chemoattractant were connected to the device
277 (green) to create a flow (*x*-direction) and perpendicular (*y*) cytokine gradient. The inset
278 shows migration of monocytes along the flow and towards the chemoattractant. (B)
279 Representative tracks of human monocytes showing the *x*- and *y*-movement of individual
280 cells upon exposure to the indicated buffer, 5 μ M CST or 0.5 nM CCL2. (C) Quantification
281 of panel B (N=3). (D) Scheme showing set-up of cremaster muscle imaging in mice to
282 visualize phagocyte (monocytes and granulocytes) extravasation *in vivo*. (E) Phagocyte
283 rolling velocity (top) and attachment (bottom) upon overflowing the muscle with buffer
284 (control, gray), 0.5 nM MIP-2 (blue) or 5 μ M CST (black) (N=3, two-way ANOVA). (F)
285 Representative images of granulocyte attachment as visualized by Ly6G-mAb (green) to
286 the vessel wall upon only buffer, MIP-2 or CST stimulation. *: P<0.05; **: P<0.01;
287 ***P<0.001; ns: not significant.
288

289 **Fig. 2: CST blocks migration induced by inflammatory chemokines and promotes**
290 **angiogenesis.** (A) Scheme showing set-up of aortic ring assay. Aortic ring was isolated
291 from CX₃CR1-GFP mice and embedded adjacent to pancreatic islets in collagen I. Image
292 shows islets (blue), CD31 (red) and CX₃CR1 (green). (B) Representative images of
293 CX₃CR1-macrophage migration upon control or CST stimulation of the aortic ring. The
294 graph shows the percentage of cells above (yellow) the center of mass (N=8). (C)
295 Representative images of vessels by CD31 (red) upon control or CST stimulation of the
296 aortic ring. (D) Quantification of angiogenesis. Total number of sprouts and branches (left)
297 and their length (right) (N=5-6). (E) Cremaster muscle imaging. Phagocyte attachment to
298 vessel wall upon overflowing the muscle with buffer (control, gray) and buffer with the
299 chemoattractant MIP-2 (blue), CST (black) or both (red) (N=3, two-way ANOVA). (F)
300 Gradientech migration assay. Representative *x*- and *y*-movement of human monocytes
301 exposed to opposite gradients of CST and CCL2 (N=3). (G) Model showing leukocyte
302 extravasation in presence of low and high concentrations of CST. Mann-Whitney test *:
303 P<0.05; **: P<0.01; ***P<0.001; ****P<0.0001; ns: not significant.
304

305 **Sup. 1: Attachment of granulocytes and monocytes to vessel wall.** (A) Venules of the
306 cremaster muscle were overflowed with bicarbonate-buffered saline buffer (buffer only
307 control), the chemoattractant MIP-2 or CST as shown in main Fig. 1D-F. Graph shows
308 quantification of rolling cells (cells/min). (B) Quantification of cell in tissue. (C)
309 Representative brightfield snapshots of *in vivo* cremaster muscle imaging as in main figure
310 1D-F. (C) Quantification of adherent granulocytes (visualized by Ly6G-mAb, main Fig.
311 1F) and monocytes (brightfield, panel C) after 0, 30, 60 and 90 minutes (N=1-2).
312


313 **Sup. 2: Quantification of CX₃CR1+ cell movement in the aortic ring model.** (A)
314 Brightfield image of the aortic ring with islets. (B) Description of CX₃CR1-cell movement
315 quantification by determination of total amount outside the aortic ring (endothelium), center
316 of mass (red spot) and the islet side (black arrow).

317
318
319
320
321
322
323
324
325
326
327
328
329
330
331


Sup. 3: Branches and sprouts in the aortic ring assay. (A) Representative images of angiogenesis quantification of main figure 2C-D. The images show the ring endothelium, main sprout (red), branch (gray) (B) Quantification of total number of sprouts and branches separately and their length (N=5-6). Mann-Whitney test *: $P < 0.05$; *** $P < 0.001$; ns: not significant.

Sup. 4: The combination of CST and MIP-2 reduced chemotaxis. Venules of the cremaster muscle were overflowed with bicarbonate-buffered saline buffer (buffer only control), the chemoattractant MIP-2 or CST, as shown in main Fig. 1D. Graph shows quantification of tissue migration (A), rolling cells (cells/min) (B) and velocity (C) upon CST, MIP-2 or stimulation with both (N=3, two-way ANOVA) *: $P < 0.05$; **: $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$; ns: not significant.

9. Figures



334



335
336

Fig. 2